» Articles » PMID: 35280766

Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Mar 14
PMID 35280766
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Traditional medicine preparations (TMPs) combined with chemotherapy is widely used for patients with advanced pancreatic cancer (APC); however, its efficacy and safety are still unclear. The purpose of this meta-analysis was to evaluate the clinical efficacy and safety of TMPs combined with chemotherapy for the treatment of APC.

Methods: A systematic search of eight electronic databases for randomized controlled trials (RCTs) was conducted from inception to October 15, 2021. Tumor response was identified as primary outcome, whereas quality of life (QoL), cancer biomarkers, and adverse drug reactions (ADRs) were identified as secondary outcomes. Quality of the evidence for each outcome was evaluated by GRADE profiler.

Results: In total, 31 RCTs involving 1,989 individuals were included. This meta-analysis showed that TMPs combined with chemotherapy significantly improved the objective response rate (ORR) (RR=1.64, 95% CI [1.43 to 1.88], p <0.00001), disease control rate (DCR) (RR=1.29, 95% CI [1.21 to 1.38], p <0.00001), and QoL (continuous data: SMD=0.81, 95% CI [0.44 to 1.18], p <0.0001, dichotomous data: RR=1.44, 95% CI [1.22 to 1.70], p<0.0001), compared to those with chemotherapy alone. In addition, the combined treatment group also had lower levels of CA19-9 (SMD=-0.46, 95% CI [-0.90 to -0.02], =0.04) and CEA (SMD=-0.55, 95% CI [-0.93 to -0.17], =0.004). Moreover, TMPs reduced the ADRs during chemotherapy.

Conclusion: This systematic review suggests that TMPs combined with chemotherapy might be a potential option to enhance therapeutic effects and reduce ADRs during the treatment of APC. However, more high-quality randomized controlled trials with more participants are needed.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=209825, identifier PROSPERO Number: CRD42021264938.

Citing Articles

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.

Wu J, Tang G, Cheng C, Yeerken R, Chan Y, Fu Z Mol Cancer. 2024; 23(1):218.

PMID: 39354529 PMC: 11443773. DOI: 10.1186/s12943-024-02136-2.


Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, open-label, randomised, controlled trial.

Han F, Wang Y, Dong X, Lin Q, Wang Y, Gao W Eur Radiol. 2023; 34(3):1481-1492.

PMID: 37796294 DOI: 10.1007/s00330-023-10210-4.


The Effects of Complementary Therapies on Patient-Reported Outcomes: An Overview of Recent Systematic Reviews in Oncology.

Mentink M, Verbeek D, Noordman J, Timmer-Bonte A, von Rosenstiel I, van Dulmen S Cancers (Basel). 2023; 15(18).

PMID: 37760483 PMC: 10526744. DOI: 10.3390/cancers15184513.


Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses.

Wang J, Wang Q, Zhang P, Zhang R, He J Front Pharmacol. 2022; 13:896017.

PMID: 36120323 PMC: 9475193. DOI: 10.3389/fphar.2022.896017.

References
1.
Guo Y, Xiao Y, Guo H, Zhu H, Chen D, Wang J . The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Aging (Albany NY). 2021; 13(14):18545-18563. PMC: 8351699. DOI: 10.18632/aging.203301. View

2.
McInnes M, Moher D, Thombs B, McGrath T, Bossuyt P, Clifford T . Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018; 319(4):388-396. DOI: 10.1001/jama.2017.19163. View

3.
Zhang X, Jiang J, Chen Z, Cao M . Silibinin inhibited autophagy and mitochondrial apoptosis in pancreatic carcinoma by activating JNK/SAPK signaling. Pathol Res Pract. 2019; 215(9):152530. DOI: 10.1016/j.prp.2019.152530. View

4.
Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E . Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol. 2012; 139(3):357-65. DOI: 10.1007/s00432-012-1336-6. View

5.
Yang Y, Li N, Wang T, Di L . Natural Products with Activity against Lung Cancer: A Review Focusing on the Tumor Microenvironment. Int J Mol Sci. 2021; 22(19). PMC: 8509218. DOI: 10.3390/ijms221910827. View